Projected Long-Term Survival High for Patients with Advanced Non_Small Cell Lung Cancer Treated with Pembrolizumab

Best Practices in Immunotherapy – June/July 2017 Vol 8

Durability of benefit—the possibility for sustained remission in patients with previously incurable disease—is already one of the hallmarks of immunotherapy. According to recent statistical analysis, however, this durability may even exceed expectations.

Based on data from multiple KEYNOTE clinical trials, Matthew D. Hellmann, MD, estimates that up to 25% of patients with advanced non–small cell lung cancer (NSCLC) who received pembrolizumab will achieve long-term survival. When compared with a long-term survival rate of just 3% to 4% for patients who received chemotherapy, these findings underscore the “remarkable step forward” made with immunotherapy, Dr Hellmann said.

“We’re cautious to use these sorts of words, but these outcomes really do start to approach the concept of cure for patients with advanced cancer,” said Dr Hellmann, a medical oncologist at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York City. “These aren’t just numbers on a curve or dots on a plot; these are patients that we see in clinic who are continuing to do well years after being given pembrolizumab.”

As Dr Hellmann reported at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, although cytotoxic chemotherapy or tyrosine inhibitors provide some meaningful anticancer responses, progression invariably occurs. With the advent of immunotherapies, however, the survival curve for patients with several advanced cancers has fundamentally changed.

“Using conventional modeling, in which we assume that everyone progresses, the proportion of patients with long-term survival is potentially zero,” said Dr Hellmann. “In the context of immunotherapy, however, progression and death is not necessarily inevitable, and long-term survival models must consider the possibility of a plateaued survival when estimating outcomes further out.”

Using medium-term survival data from the KEYNOTE-001 and KEYNOTE-010 studies, in which previously treated PD-L1–positive patients with NSCLC were given pembrolizumab, Dr Hellmann and colleagues projected the percentage of patients who would achieve long-term survival.

“Our approach was to take an initial estimate of long-term survival in patients treated in KEYNOTE-001 and then independently examine data from KEYNOTE-010 to validate the reproducibility of that estimate,” Dr Hellmann explained.

With this model, based on KEYNOTE-001 data, the researchers estimated that 25.4% of patients on pembrolizumab therapy would survive long-term. Further analysis of KEYNOTE-010 cutoff data, which included 6 additional months of patient follow-up, found a long-term survival estimate of 21.5%. By contrast, docetaxel chemotherapy has an estimated long-term survival rate of 3% to 4% in the same patient population.

“The lives and the expectations of these patients have remarkably changed,” said Dr Hellmann, who emphasized that this is just the beginning of research into immunotherapy’s survival benefit.

“We’ve got a lot of work to do in understanding with precision who these people are in the tail of the curve so that we can get them the right therapy from the start. We also need to identify better therapeutic combinations in order to raise that curve further, but this is a good start,” Dr Hellmann concluded.

Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country